Ultrathin drug-eluting stents performed better than their thicker counterparts in a recent analysis of the BIO-RESORT trial, researchers reported in JAMA Cardiology May 21—but thinner struts might not always be the right go-to for patients after PCI.

Corindus Vascular Robotics’ CorPath GRX system—the world’s only FDA-approved and CE-marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention—was used in the first-ever live transmission of a robotic PCI in Europe during this year's EuroPCR congress.

Three-year results of the BIO-RESORT study, presented at EuroPCR this week in Paris, put Biotronik’s ultrathin Orsiro stent ahead of two other competitors in terms of target lesion failure and revascularization.

The European Association of Percutaneous Cardiovascular Interventions (EAPCI) has published a clinical guidance statement regarding the use of intra-coronary imaging (IC), sharing the document during its EuroPCR Annual Meeting, May 21-24 in Paris.

The bioresorbable vascular scaffold, once an exciting prospect for cardiologists, saw a unique rise and fall in popularity within a year of its introduction to the CV market.

Atrial fibrillation patients with coronary artery disease pose a delicate balancing act for physicians. A growing awareness of bleeding vs. ischemic risks could soon lead to a steadier therapeutic response.

Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.

Coronary artery bypass grafting (CABG) surgery beat out stent placement with percutaneous coronary intervention (PCI) in a recent study of patients with multivessel coronary artery disease. Patients saw lower risks of death, hospital readmission and revascularization with the former procedure.